132 results about "Kidney cell" patented technology

The invention relates to the technical field of cytology, in particular to a grass carp brain astrocyte line and application thereof, the grass carp brain astrocyte line is preserved in China Center for Type Culture Collection on May 7, 2025, and the preservation number of the grass carp brain astrocyte line is CCTCC NO: C2025149. The grass carp brain astroglia cell line provided by the invention has the capability of efficiently proliferating GCRV-II, and the virus titer of the GCRV-II replicated in the cell line at least can reach 1.38 * 10 < 8 > pfu / mL or above; after the GCRV-II is blindly passed for 5 generations in a grass carp astroglia cell line, the grass carp can still have typical bleeding symptoms and death due to the virus. And the exogenous plasmid transfected grass carp brain astroglia cell line has similar transfection efficiency to commercial grass carp kidney cells. Therefore, the invention lays an important foundation for deep research of pathogenic mechanism of GCRV-II, vaccine preparation, antiviral drug screening and prevention and control of grass carp viral hemorrhagic disease.

The invention discloses a variable region amino acid sequence of a monoclonal antibody of a West Nile virus non-structural protein NS1 and application of the variable region amino acid sequence, and belongs to the technical field of medicines. According to the invention, West Nile virus non-structural protein NS1 expressed by human embryo kidney 293 cells is used as an antigen to immunize a rabbit, B cells capable of being specifically combined with the West Nile virus non-structural protein NS1 are screened from rabbit spleen cells through flow sorting, and a signal peptide and a variable region gene fragment of an antibody are cloned through reverse transcription-polymerase chain reaction; according to the present invention, the non-structural protein NS1 of flaviviridae flaviviridae virus is taken as a template, and is connected with a constant region gene to an expression vector, and after mammalian cell expression and purification, the monoclonal antibody which has high affinity and is not combined with the non-structural protein NS1 of other eight viruses of flaviviridae flaviviridae virus is obtained through enzyme-linked immunosorbent assay; the monoclonal antibody has application value in diagnosis and prevention and treatment of West Nile virus infection.

The invention discloses a cat kidney suspension culture cell line suitable for serum-free suspension culture and application of the cat kidney suspension culture cell line. The name of the cell line is F81-B4, and the preservation number is CGMCC (China General Microbiological Culture Collection Center) No.46350. After 50 generations of continuous subculture, the cells still can maintain the original proliferation level and cellular morphology, the cell number can reach 9.0 * 10 < 6 > / mL after the cells are subcultured at the density of 1.0 * 10 < 6 > / mL for three days, the multiplication time is 22-26 hours, and the cell proliferation speed is equivalent to that in a shake flask when the cells are amplified to a 10L bioreactor for culture. The cell line is highly susceptible to feline parvovirus, feline calicivirus, feline herpes virus, canine parvovirus and canine distemper virus, the virus content of a virus solution harvested 72 h after FPV virus inoculation can reach 107.5 TCID50 / mL, the virus content of a virus solution harvested 24 h after FCV virus inoculation can reach 1010.8 TCID50 / mL, the virus content of a virus solution harvested 48 h after FHV-1 virus inoculation can reach 107.5 TCID50 / mL, compared with an existing F81 adherent cell production process, the production process has the advantages that the production efficiency is high, and the production cost is low. The method has the characteristics of rapid lesion, short virus collection time and high titer. The cell matrix is an ideal cell matrix which can be used for culturing the three viruses.

The invention belongs to the technical field of biological medicine, and particularly relates to an in-vitro fusion technology for multi-lineage human kidney organs and application thereof. The invention provides a method for realizing culture of multilineage kidney organs by fusing kidney units and ureteral bud organs in vitro. According to the in-vitro fusion technology of the kidney organoid reported by the invention, two organoid with different pedigree sources, namely the kidney unit and the ureteral bud, can be efficiently fused, a UB tubular structure is integrated into the kidney unit organoid, and the UB tubular structure starts from a single ureteral bud and is wrapped by kidney unit precursor cells in a similar in-vivo development process, and finally develops into a kidney with glomerulus and a plurality of kidney cells. The multi-lineage renal organ comprises a catheter, a proximal tube, a marrow tab thin section, a distal tube, a connecting tube and a ureteral bud with a single outlet. A framework is provided for an engineered renal unit and a smooth collection system, and the method is an important step for generating the functional renal tissue from the beginning.

The invention discloses a polyketone compound derived from actinomycetes as well as a preparation method and application thereof, and relates to the technical field of microbial natural product mining and biological medicine, and the key point of the technical scheme is that the invention discloses a novel polyketone compound Strepactone derived from actinomycetes Streptomyces sp. DP0001, and the molecular formula of the novel polyketone compound Strepactone is C25H38O5. The compound is obtained through strain fermentation, ethyl acetate extraction and multi-step chromatographic purification, and the structure is identified through ESI-MS, 1H NMR and 13C NMR. Experiments show that Strepactone has an inhibition effect on staphylococcus aureus and methicillin-resistant staphylococcus aureus and has remarkable inhibition activity on human non-small cell lung cancer A549 cells, the half inhibitory concentration IC50 of the Strepactone is 5.36 mu M, and the Strepactone has no obvious cytotoxic activity on human embryo kidney cells 293T cells at the concentration of 30 mu M. The compound provided by the invention can be used for preparing anti-drug-resistant bacteria drugs and anti-human non-small cell lung cancer drugs, and also provides a structural basis for the development of novel antibacterial and anti-tumor leading drugs.

The present invention relates to lipid nanoparticle (LNP) compositions, as well as diagnostic or therapeutic polynucleotides, such as TERT mRNA, that can be delivered in a formulation together with the LNP compositions to various tissue and cell types in the whole body of a mammal, such as, for example, TNP mRNA. Comprising stem cells, progenitor cells, germ cells, differentiated cells or terminally differentiated cells, cancer cells, endothelial cells, epithelial cells, splenic cells, hepatocells, kidney cells and / or osteoblasts, for example, for use in the diagnosis, prevention and / or treatment of a condition or disease.

The invention discloses application of CFB polypeptide as a target spot in preparation of diabetic nephropathy diagnosis and treatment medicines, and belongs to the technical field of biological medicines. The invention provides application of CFB (circulating fluid bed)-sourced polypeptide in preparation of a medicine for treating diabetic nephropathy and application of the CFB-sourced polypeptide as a possible target in development of a novel diabetic nephropathy biomarker. According to the invention, a complement factor B-derived polypeptide which is significantly up-regulated in diabetic nephropathy is found through deep peptidomics analysis; furthermore, a functional experiment proves that the polypeptide shows remarkable anti-fibrosis activity in kidney cells for the first time, the active oxygen level can be reduced, and an HIF-1 alpha / glycolytic pathway can be regulated and controlled.

The invention discloses a chikungunya virus envelope E2 protein monoclonal antibody and application thereof, and belongs to the technical field of medicines. The chikungunya virus envelope protein E2 expressed by human embryo kidney 293 cells is used as an antigen to immunize a rabbit, B cells capable of being specifically combined with the chikungunya virus envelope protein E2 are screened from rabbit spleen cells through flow sorting, and signal peptide and variable region gene fragments of an antibody are cloned through reverse transcription-polymerase chain reaction. According to the present invention, the chikungunya virus-resistant monoclonal antibody with high neutralizing activity and capable of 100% protection of mice against chikungunya virus lethal attack is obtained by carrying out enzyme-linked immunosorbent assay, in-vitro virus neutralization and mouse toxicity attack experiment after mammalian cell expression and purification, and the recombinant chikungunya virus-resistant monoclonal antibody has characteristics of high neutralizing activity and high immunogenicity, and can be used for preparing the chikungunya virus-resistant monoclonal antibody, and the recombinant chikungunya virus-resistant monoclonal antibody. The monoclonal antibody has application value in prevention and treatment of yellow fever.

A recombinant humanized collagen type III alpha-1 (rhCol III a1), and an expression vector and use thereof are provided, relating to the technical field of bioengineering. A sequence on positions 154 to 1,221 of a human type III collagen α chain is ligated to an optimized vector pcDNA3.1, a resulting optimized expression vector is transfected into a human embryonic kidney cell Expi293F, and then rhCol III a1 is secreted to form a fusion protein with a soluble green fluorescent protein (GFP). The expressed rhCol III a1 that forms the fusion protein with the GFP shows an activity of promoting the migration of BALB / c 3T3 cells, thus exhibiting a great application potential in the field of skin care.

The invention discloses preparation and application of a therapeutic drug for preventing and treating heart failure or myocardial ischemia-reperfusion injury. Research results of the invention show that the exosome secreted by kidney cells after stimulation and induction of the drug-containing serum of Zhenwu decoction has a myocardial protection effect. Therefore, the invention provides a novel candidate drug for heart failure or myocardial ischemia-reperfusion injury.

The invention discloses a yellow fever virus envelope protein monoclonal antibody and application thereof, and belongs to the technical field of medicines. Yellow fever virus envelope protein E expressed by human embryo kidney 293 cells is used as an antigen to immunize a rabbit, B cells capable of being specifically combined with the yellow fever virus envelope protein E are screened from rabbit spleen cells through flow sorting, and signal peptide and variable region gene fragments of an antibody are cloned through reverse transcription-polymerase chain reaction. According to the present invention, the monoclonal antibody with high neutralizing activity and capable of completely protecting mice from yellow fever virus lethal attack is obtained by using the monoclonal antibody as a template, connecting the monoclonal antibody and the constant region gene to an expression vector, carrying out mammalian cell expression and purification, and carrying out enzyme-linked immunosorbent assay, in-vitro virus neutralization and mouse virus attack experiment, such that the monoclonal antibody has high neutralizing activity and can completely protect mice from yellow fever virus lethal attack; the monoclonal antibody has application value in prevention and treatment of yellow fever.

The invention provides a composition for promoting ATP (adenosine triphosphate) generation and improving kidney energy metabolism by activating an AMPK / PGC-1alpha pathway. The composition is prepared from the following raw materials in parts by weight: 100 to 400 parts of herba cistanche, 50 to 200 parts of radix astragali seu hedysari, 25 to 100 parts of glycine betaine and 150 to 300 parts of alpha-ketoglutaric acid. The invention further provides a preparation method and application of the composition for improving ATP generation and improving kidney energy metabolism by activating the AMPK / PGC-1alpha pathway. Through combined use of cistanche, astragalus membranaceus, betaine and alpha-ketoglutaric acid, a multi-target synergistic mechanism of AMPK activation, metabolic substrate supplementation and epigenetic regulation is formed, the mitochondrial function and ATP generation of kidney cells are comprehensively improved, the limitation of existing single-component or chemical drugs is broken through, a safer and more efficient intervention strategy is provided for kidney energy metabolism disorders, and the clinical application prospect is broad. The invention provides an innovative solution for renal tubular energy disorder, has dual values of metabolic regulation and kidney protection, and conforms to the development trend of natural medicines. The invention belongs to the technical field of food and health care product processing.

The invention discloses an emblic leafflower fruit milk processing technology optimization method based on a single factor and pharmacodynamic experiment, and belongs to the technical field of traditional Chinese medicine processing, and the method comprises the following steps: screening out optimal technological parameters through the single factor experiment: mixing emblic leafflower fruit and raw milk according to a material-liquid ratio of 1: 15, soaking at 45 + / -5 DEG C for 12 hours, cleaning milk stains, naturally air-drying for 2 hours, and drying at 50 DEG C for 24-48 hours until the water content is less than 6%. A liquid chromatography-tandem high-resolution mass spectrometry technology is adopted for analysis and displaying that the content of gallic acid, ellagic acid and corilagin in a processed product is remarkably reduced. Pharmacodynamic experiments prove that the toxicity of the processed product to WRL68 hepatocytes and 293T renal cells is weakened, the survival rate of the hepatocytes and the renal cells is increased along with reduction of the concentration of the components, and the toxicity reduction effect is achieved. The technological parameters are clear, the quality is stable, and a scientific basis is provided for standardized production and clinical safe medication of emblic leafflower fruit milk processing.

The invention relates to the technical field of diagnosis, in particular to a prognosis evaluation kit and evaluation method for renal cell carcinoma patients based on DNAJA1 protein expression quantity. The method for evaluating the prognosis and immune microenvironment state of the RCC patient based on the DNAJA1 expression level provided by the invention has good stability, accuracy and operability, can realize hierarchical management and individualized treatment guidance of patient risks, and has remarkable clinical and social values.

The application discloses application of sodium butyrate in preparation of a medicine for preventing and treating grass carp hemorrhagic disease, wherein a structural formula of the sodium butyate is molecular formula C4H7NaO2, and a CAS number is 156-54-7; and the application further provides a medicine composition which comprises an effective dose of the sodium butyrate as an active ingredient, and further comprises a pharmaceutically acceptable carrier or excipient, and the dosage form comprises tablets, granules, powders, powders, suspensions, oral liquids, and the concentration of the sodium butyrate is 0.1-20 mM. Through a cell experiment, it is found that the sodium butyrate can significantly inhibit replication of grass carp reovirus in grass carp kidney cells, and improve expression of immune genes of the grass carp kidney cells, and it is proved that the sodium butyrate has a high efficient inhibiting effect on infection of the grass carp reovirus, and has the advantages of high safety and wide application prospect for preparing the medicine for preventing and treating the grass carp hemorrhagic disease caused by the grass carp reovirus.

The application discloses a kind of kidney cell cancer patient prognosis risk prediction methods based on multi-modal deep learning.The present application processes whole field digital pathology section (WSI) image and pathological diagnosis report by deep learning algorithm, extracts text features using natural language processing model, extracts image features using computer vision model and ABMIL network, and carries out multi-modal feature fusion through Cross-attention Transformer network, and finally outputs the survival risk curve of patient changes with time in combination with Weibull survival function, for assisting doctor to carry out more accurate prognosis evaluation and survival analysis.

The invention relates to the technical field of preparation of antibacterial materials, in particular to a two-dimensional nickel (II) coordination polymer as well as a preparation method and antibacterial application thereof. The preparation method comprises the following steps: mixing a dpb solution, a btc solution, a Ni (NO3) 2 solution, acetonitrile and water, carrying out a solvothermal reaction for 4-5 days, carrying out natural cooling crystallization, washing and drying to obtain [Ni3 (dpb) 2 (btc) 2 (H2O) 2] n, and according to the complex, nickel (II) has two coordination modes, and nickel (II) is coordinated with carboxyl oxygen atoms of two trimesic acid, oxygen atoms of two water molecules and nitrogen atoms of two ligands; nickel 2 (II) is coordinated with three nitrogen atoms of a ligand and three oxygen atoms of two trimesic acids to form a one-dimensional ladder-shaped chain structure, and the ladder-shaped chain is further bridged with the ligand to form a two-dimensional layered structure. The compound has very good thermal stability, has a good inhibition effect on staphylococcus aureus and escherichia coli, is non-toxic to human embryo kidney cells in 24 hours and 48 hours, and can be used as a bacteriostatic drug material carrier in the aspect of medicine.

The invention discloses a folium cortex eucommiae extract and application of the folium cortex eucommiae extract in prevention and treatment of adriamycin nephropathy, and relates to the technical field of medicines, the folium cortex eucommiae extract is prepared from dried folium cortex eucommiae through water extraction, heating at 65 DEG C, ultrasonic assistance and vacuum freeze drying, LC-MS / MS analysis shows that the folium cortex eucommiae extract contains no less than 200 components, the components mainly comprise flavonoids, terpenes and phenylpropanoids, and the content of the flavonoids, the terpenes and the phenylpropanoids is no less than 100%. The folium cortex eucommiae extract has no obvious cytotoxicity to HK-2 and HBZY-1 cells under the concentration of 0-1500mu g / mL, can be used for preparing medicines for preventing and treating adriamycin nephropathy, inhibits kidney cell apoptosis by down-regulating Bax and up-regulating Bcl-2 and obviously reduces the levels of IL-6, IL-1beta and TNF-alpha in serum, and in an animal model, 150-600mg / kg of the folium cortex eucommiae extract is continuously administrated for 21-30 days in an intragastric manner, so that the effect of preventing and treating adriamycin nephropathy is achieved. The traditional Chinese medicine composition can effectively relieve weight loss, reduce urine protein, serum creatinine and urea nitrogen, increase albumin and improve kidney pathological injury, and is suitable for relieving kidney toxicity in a prophylactic or therapeutic mode in subjects receiving adriamycin chemotherapy.

The invention discloses application of rhizoma osmundae in prevention and treatment of ichthyophthiriasis of aquaculture animals, toxicity experiments of rhizoma osmundae on grass carp kidney cells (CIK) show that the maximum non-toxic concentration of an aqueous extract of rhizoma osmundae on the CIK cells is 1200 [mu] g / mL, and the inhibition of the aqueous extract of rhizoma osmundae on the survival rate of a grazing body of ichthyophthiriasis has dose correlation. When the concentration of the medicine reaches 100 mg / L (mu g / mL), the death rate of the grazing body reaches 100%, and in addition, calculation shows that the median lethal concentration (LD50) of the rhizoma osmundae aqueous extract to the ichthyophthirius multifiliis grazing body is 13.256 mg / L. The application of the rhizoma osmundae in inhibiting the survival rate of the ichthyophthirius multifiliis of the fish under the cell non-toxic concentration is provided for the first time, a novel medicine is provided for preventing and treating ichthyophthirius multifiliis infection of aquaculture animals, and the rhizoma osmundae is a natural medicinal plant, is environmentally friendly and has the advantages of reducing the risk of medicine residues and the like.

The invention discloses an antibacterial peptide, a pharmaceutical composition and application, and belongs to the field of polypeptide medicines.The antibacterial peptide forms a novel annular conformation by introducing n-leucine and 2-aminobutyric acid to construct a parent nucleus structure. The affinity of the antibacterial peptide to the main component phosphatidylglycerol of a bacterial cell membrane is remarkably improved, is improved by 31 times or more compared with polymyxin B and is improved by 16 times or more compared with D50 peptide, and the selectivity of the antibacterial peptide to the main component phosphatidylcholine of a mammalian cell membrane is improved by hundreds of times or more compared with that of a control peptide. The polymyxin B peptide has extremely low toxicity to HK-2 kidney cells, and the biological safety of the polymyxin B peptide is obviously superior to that of polymyxin B and D50 peptide. The minimum inhibitory concentration of the antibacterial peptide to gram-negative bacteria is as low as 0.03 mu g / mL, is about 33 times higher than that of polymyxin B, and is 17-33 times higher than that of D50 peptide. The treatment effect of the antibacterial peptide is obviously superior to that of polymyxin B and D50 peptide in various infection models, and the antibacterial peptide is expected to be developed into a novel anti-infection drug and is used for preventing and treating various infections.

Described herein are systems, methods, and interconnecting porous hydrogel blocks for ex vivo kidney tissue generation. A block may comprise a 3D continuous polymeric matrix with a network of microporous cavities, and may be configured to interconnect with at least one other block. A system may comprise at least one block and be configured to cultivate one or more kidney-like organ components when seeded with at least one HEK293 cell and at least one kidney cell isolated from at least one specimen. A method may comprise seeding at least one block with at least one HEK293 cell and at least one kidney cell isolated from at least one specimen

Provided herein are, inter alia, extracellular products (e.g., vesicles such as microvesicles, e.g., exosomes) produced by renal cells (such as bioactive renal cells, e.g., selected renal cells). Methods of altering components (such as miRNAs or proteins) of vesicles produced by cells, as well as methods of producing vesicles comprising various compounds are also included. Also provided are diagnostic and treatment methods

A method of identifying an enriched heterogeneous kidney cell population having therapeutic potential, an enriched heterogeneous kidney cell population having therapeutic potential and uses thereof.

Provided herein are, inter alia, extracellular products (e.g., vesicles such as microvesicles, e.g., exosomes) produced by renal cells (such as bioactive renal cells, e.g., selected renal cells). Methods of altering components (such as miRNAs or proteins) of vesicles produced by cells, as well as methods of producing vesicles comprising various compounds are also included. Also provided are diagnostic and treatment methods.

This invention discloses a targeted adjuvant influenza vaccine composition for atrial fibrillation patients with atrial fibrosis. The vaccine antigen components are selected from the surface antigens of currently prevalent influenza virus strains, such as hemagglutinin (HA) and neuraminidase (NA). High-purity influenza virus antigens are prepared through cell culture or recombinant DNA technology. For example, influenza virus is cultured using Madin-Darby canine kidney (MDCK) cells, and purified through centrifugation, filtration, and chromatography to obtain high-purity HA and NA antigens. After injection into the human body, the influenza virus antigens (HA and NA) are taken up and processed by antigen-presenting cells (such as macrophages and dendritic cells). The antigen-presenting cells present antigen peptides to T lymphocytes and B lymphocytes, activating a specific immune response. B lymphocytes differentiate into plasma cells with the help of T lymphocytes, producing specific antibodies that recognize and bind to the influenza virus, preventing it from infecting host cells and thus preventing influenza virus infection.

The invention discloses an antibacterial peptide, a pharmaceutical composition and application, and belongs to the field of polypeptide medicines.The antibacterial peptide forms a novel annular conformation by introducing n-leucine and 2-aminobutyric acid to construct a parent nucleus structure. The affinity of the antibacterial peptide to the main component phosphatidylglycerol of a bacterial cell membrane is remarkably improved, is improved by 31 times or more compared with polymyxin B and is improved by 16 times or more compared with D50 peptide, and the selectivity of the antibacterial peptide to the main component phosphatidylcholine of a mammalian cell membrane is improved by hundreds of times or more compared with that of a control peptide. The polymyxin B peptide has extremely low toxicity to HK-2 kidney cells, and the biological safety of the polymyxin B peptide is obviously superior to that of polymyxin B and D50 peptide. The minimum inhibitory concentration of the antibacterial peptide to gram-negative bacteria is as low as 0.03 mu g / mL, is about 33 times higher than that of polymyxin B, and is 17-33 times higher than that of D50 peptide. The treatment effect of the antibacterial peptide is obviously superior to that of polymyxin B and D50 peptide in various infection models, and the antibacterial peptide is expected to be developed into a novel anti-infection drug and is used for preventing and treating various infections.

The invention belongs to the technical field of virus infection cell lines, and particularly relates to a rats kidney cell line and application thereof. Wherein the preservation number of the kidney cell line of the rats with the yellow chest is CCTCC (China Center For Type Culture Collection) NO: C2025271. The rats kidney cell line (RtK-15W) provided by the invention has multiple advantages of high sensitivity, high replication efficiency, quantitative detection, passage stability and the like on arenavirus; a reliable cell tool and an efficient, reliable and generalizable experimental platform are provided for separation and identification, in-vitro amplification, titer determination, pathogenesis research, drug screening, antibody neutralization experiment, vaccine effect evaluation and the like of arenaviruses (including lymphocytic choriomeningitis virus (LCMV) and Wenzhou virus (WENV)).

This invention discloses a cell line capable of inhibiting African swine fever virus (ASFV) replication and its construction method, relating to the field of biotechnology. The construction method includes the following steps: knocking out the ANXA1 gene in African green monkey kidney cells to construct a stably inherited ANXA1 gene knockout cell line; this ANXA1 gene knockout cell line is the cell line capable of inhibiting ASFV replication. The cell line provided by this invention can significantly inhibit ASFV replication. Compared to existing porcine cell lines, this cell line has a clear background, is free from endogenous porcine pathogen contamination, and can be passaged indefinitely, solving the problems of cumbersome porcine cell preparation and large batch-to-batch variations. Simultaneously, this cell line provides a targeted cell model for studying the replication mechanism of ASFV and establishes an efficient evaluation system for high-throughput screening of anti-ASFV drugs, thereby facilitating the development of research related to ASFV prevention and control.

The invention discloses a chikungunya virus monoclonal antibody and application thereof in preparation of preventive and therapeutic antibody drugs, and belongs to the technical field of medicines. The chikungunya virus envelope protein E2 expressed by human embryo kidney 293 cells is used as an antigen to immunize a rabbit, B cells capable of being specifically combined with the chikungunya virus envelope protein E2 are screened from rabbit spleen cells through flow sorting, and signal peptide and variable region gene fragments of an antibody are cloned through reverse transcription-polymerase chain reaction. According to the present invention, the chikungunya virus-resistant monoclonal antibody with high neutralizing activity and capable of 100% protection of mice against chikungunya virus lethal attack is obtained by carrying out enzyme-linked immunosorbent assay, in-vitro virus neutralization and mouse toxicity attack experiment after mammalian cell expression and purification, and the recombinant chikungunya virus-resistant monoclonal antibody has characteristics of high neutralizing activity and high immunogenicity, and can be used for preparing the chikungunya virus-resistant monoclonal antibody, and the recombinant chikungunya virus-resistant monoclonal antibody. The monoclonal antibody has application value in prevention and treatment of yellow fever.

The invention discloses a G protein coupled receptor family membrane receptor GPR40 related to eukaryotic expression and glycometabolism effect, and a method for extracting and detecting the concentration of a compound combined with the GPR40 receptor in a cell based on the affinity of receptor protein. The detection method comprises the following steps: eukaryotically expressing a membrane receptor GPR40 protein with a Flag tag in a human embryonic kidney cell HEK293, and after perfluorooctane sulfonic acid (PFOS) is exposed, extracting and purifying a GPR40-PFOS compound in a cell lysis solution by utilizing Protein G magnetic beads and a Flag antibody; after uncombined PFOS is washed away by a cracking buffer solution containing a protease inhibitor, acetonitrile is added, and PFOS in the compound is extracted; and centrifuging and treating with a 0.22 mu m filter membrane, and detecting the concentration of the PFOS by using a high performance liquid chromatography-mass spectrometer (HPLC-MS / MS). The method can directly detect the concentration of PFOS combined with the GPR40 receptor, can be used for screening other perfluorinated compounds and environmental pollutants which potentially act on the GPR40 receptor to play a glycometabolism effect, can simplify the steps of effect-oriented analysis, and plays an important role in compound recognition and screening.